STAT+: Cassidy criticizes FDA oversight of abortion pill manufacturers in new report

STAT PlusBreaking News Cassidy criticizes FDA oversight of abortion pill manufacturers in new report The report adds to GOP calls for Trump administration to rein in mifepristone Manage alerts for this article Email this article Share this article By Margaret MantoAug. 27, 2026 Washington Correspondent Margaret Manto[email protected]Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61.

WASHINGTON — Sen. Bill Cassidy (R-La.) released a report on Thursday criticizing the Food and Drug Administration for not tightening restrictions on the abortion pill mifepristone, and charging the agency with lackluster oversight of the companies that manufacture the drug. “To this day, FDA continues to redact mifepristone-related records in an unprecedented manner,” the report claims.

“This lack of transparency has led to unanswered questions.” Advertisement The report is the result of an investigation conducted by Cassidy and other Republicans on the Senate’s health committee into the compliance practices of Danco, which distributes the brand-name version of mifepristone, and two other companies that manufacture generic versions of the drug. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%!

2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In Congress, FDA, Pharmaceuticals, Policy, public health, reproductive health, STAT+ Submit a correction requestReprints Margaret Manto Washington Correspondent Margaret is a Washington correspondent covering the Food and Drug Administration and other federal health agencies. Reach her on Signal at margaretmanto.61.

Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Recommended Biotech August 26, 2026 STAT Plus: FDA approves new pancreatic cancer drug expected to usher in new era of treatment Health August 21, 2026 STAT Plus: HHS document offers new clues to Kennedy’s vaccine plans Advertisement Biotech August 19, 2026 STAT Plus: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial Pharma August 18, 2026 STAT Plus: Trump expected to pick White House adviser Heidi Overton to lead FDA Health August 18, 2026 Fauci adviser David Morens pleads guilty to avoiding records requests, conspiracy to defraud government Subscriber Picks